UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1259-7
Program Prior Authorization/Notification
Medication Mulpleta® (lusutrombopag)
P&T Approval Date 9/2018, 10/2019, 10/2020, 10/2021, 10/2022, 10/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Mulpleta (lusutrombopag) is a thrombopoietin receptor agonist indicated for the treatment of
thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a
procedure.
2. Coverage Criteriaa:
A. Thrombocytopenia
1. Mulpleta will be approved based on all of the following criteria:
a. Diagnosis of thrombocytopenia
-AND-
b. Patient has chronic liver disease
-AND-
c. Patient is scheduled to undergo a procedure
Authorization will be issued for 1 month.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
© 2024 UnitedHealthcare Services, Inc.
1
4. References:
1. Mulpleta [Package Insert]. Florham Park, NJ: Shionogi, Inc.; April 2020.
Program Prior Authorization/Notification - Mulpleta (lusutrombopag)
Change Control
9/2018 New program.
10/2019 Annual review with no change to clinical coverage criteria. Update to
reference.
10/2020 Annual review. No change to clinical criteria. Updated reference.
10/2021 Annual review with no change to clinical coverage criteria.
10/2022 Annual review with no change to clinical coverage criteria. Added state
mandate footnote.
10/2023 Annual review with no change to clinical coverage criteria.
10/2024 Annual review with no change to clinical coverage criteria.
© 2024 UnitedHealthcare Services, Inc.
2